Acalabrutinib Safe, Effective in Ibrutinib-Intolerant CLL/SLL

“Based on these preliminary findings, we feel that acalabrutinib has promising activity in this group of patients, and safety, and it’s effective very quickly and it appears at least in the early follow-up to have durability,” said Awan, associate professor, division of hematology, department of internal medicine, Ohio State University.


3 Replies

  • Thanks for posting these!!!

  • I love repeating great news!👍🏻🎉🍻

  • Anxious to hear more on Acalabrutinib in Complex Karyotype with unmutated and Notch1 in frontline.

You may also like...